![]() ![]() The soft backlog is about EUR250 million, down from the 2021 figure when it was EUR281 million, due to backlog conversions recorded during the year. The backlog is EUR116 million, up 3.0 percent from the 2021 figure when it was EUR113 million. The reduction in cash is attributable, on the one hand, "to the increase in the value of raw material inventories resulting from the increase in the cost of the aforementioned materials, and to the increase in receivables from customers resulting from price revisions, only partially invoiced and collected during the year," the company explains. The Consolidated Net Financial Position was positive by about EUR10 million, down from the Decemfigure of EUR18.7 million. The worsening of margins recorded during 2022 "is attributable to the generalized increase in the cost of the main production factors, first and foremost raw materials and energy, only partly offset by the price revision formulas provided for in longer-term contracts and by some commercial renegotiations concluded the main customers," a note says. This result, although down about 13% from the 2021 figure of EUR15.7 million, was better than market estimates. and the remaining 8 percent in other countries.Īt the product level, 84% is furniture, followed by 7% toilets and 6% fairings.Įbitda stands at about EUR13.5 million, with an Ebitda margin of about 21%. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.įusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.The value of production was 56 percent in Italy, 20 percent in France, 9 percent in Germany, 7 percent in the U.S. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Trading on margin increases the financial risks.īefore deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.įusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. ![]() Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications. ![]() Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros Corporation is a clinical-stage biopharmaceutical company.
0 Comments
Leave a Reply. |